What other metabolic disorders can cause isolated hypercalcemia besides primary hyperparathyroidism and malignancy?

Metabolic Disorders Causing Isolated Hypercalcemia

Beyond primary hyperparathyroidism and malignancy, the key metabolic disorders causing isolated hypercalcemia include familial hypocalciuric hypercalcemia (FHH), hypervitaminosis D from granulomatous diseases, and several rare genetic disorders—each distinguished by PTH levels and specific biochemical patterns. 1

Algorithmic Approach Based on PTH Levels

Hypercalcemia with Normal or Elevated PTH

Familial Hypocalciuric Hypercalcemia (FHH) is the primary metabolic disorder to consider when PTH is inappropriately normal or mildly elevated 1:

• Mechanism: Inactivating mutations in calcium-sensing receptor genes (CASR for FHH1, GNA11 for FHH2, AP2S1 for FHH3) 1
• Key distinguishing feature: Normal urinary calcium excretion (not truly "hypocalciuric" as the name suggests—calciuria matches healthy subjects) 1
• Critical pitfall: Calciuria ranges overlap significantly between FHH and primary hyperparathyroidism, making differentiation difficult on this criterion alone 1
• Autoimmune variant: Rare anti-CaSR receptor antibodies can cause similar presentation 1

Hypercalcemia with Suppressed or Low PTH

When PTH is non-elevated or suppressed, six main metabolic/endocrine etiologies emerge 1:

1. Hypervitaminosis D from Granulomatous Diseases

This represents the most clinically significant non-malignant metabolic cause 1:

• Mechanism: Excessive, unregulated calcitriol production by granulomatous tissue or macrophages via extra-renal 1-alpha-hydroxylase 1
• Specific conditions: Sarcoidosis (10% develop hypercalcemia, 30% have hypercalciuria), tuberculosis, fungal granulomas, berylliosis, lymphomas, pneumocystosis 1, 2
• Biochemical signature: Elevated phosphate due to increased intestinal phosphate absorption 1
• Treatment response: Corticosteroids cause prompt reversal; alternatives include chloroquine, hydroxychloroquine, or ketoconazole if steroids fail 2

2. Genetic Metabolic Disorders

Several rare inherited conditions cause hypercalcemia with suppressed PTH 1:

Childhood idiopathic hypercalcemia type 1:

• Bi-allelic CYP24A1 gene variants affecting vitamin D catabolism
• Results in elevated 1,25-(OH)₂D 1

Mahvash syndrome:

• Glucagon receptor (GCGR) gene variants 1

Williams-Beuren syndrome:

• Chromosome 7 microdeletion
• 15% develop moderate infantile hypercalcemia (resolves before age 4)
• Associated with mental retardation and cardiovascular abnormalities 1

Jansen's metaphyseal chondrodysplasia:

• Activating PTH1R gene variants (iPPSD1)
• Hypercalcemia typically only between 1 month and 10 years of age
• Normal calcium at birth and in adulthood 1

Congenital lactose intolerance:

• Lactase or iso-maltase deficiency (autosomal recessive)
• Neonatal digestive disorder with increased intestinal calcium absorption 1

Hypophosphatasia:

• ALPL gene mutation
• Diagnostic signature: Hypercalcemia AND hyperphosphatemia with LOW alkaline phosphatase 1

3. Immobilization Hypercalcemia

A metabolic consequence of prolonged immobility 1:

• Timing: Occurs 4-6 weeks after immobilization onset, sometimes several months later
• High-risk populations: Young adults after spinal cord trauma; poly-pathological elderly
• Mechanism: Reduced mechanical stimulation of osteoblasts → increased sclerostin → Wnt pathway inhibition → predominant osteoclastic resorption 1

4. Liver Dysfunction (Cirrhosis)

Hypercalcemia occurs in chronic or acute liver decompensation 1:

• Prognostic significance: Generally associated with increased mortality 1
• Mechanism: Release of inflammatory cytokines and prostaglandins; may relate to concurrent immobilization 1
• Biochemical pattern: No increase in circulating PTH or vitamin D 1

5. Endocrinopathies

Various endocrine disorders induce hypercalcemic tendency with non-elevated PTH 1:

• Adrenal insufficiency: Can present with hypercalcemia, hyperphosphatemia, and suppressed PTH
• Thyrotoxicosis: Increased bone turnover
• These require specific endocrine evaluation when suspected

6. Drug-Induced Hypercalcemia

While not detailed extensively in the guidelines, thiazide diuretics deserve mention 3:

• Decrease renal calcium loss
• May precipitate hypercalcemia in mild primary hyperparathyroidism
• Requires periodic monitoring of calcium and PTH 3

Critical Clinical Pearls

Before attributing hypercalcemia to any metabolic disorder, systematically exclude confounding factors 4:

• Vitamin D deficiency (limits calcitriol production, affects presentation)
• Renal insufficiency (prevents calcitriol production, normalizes calciuria in hyperparathyroidism)
• Malabsorption or very low-calcium diet
• Corticosteroid therapy
• Excessive vitamin D or calcium supplementation

Common diagnostic pitfall: In cancer patients, don't anchor on malignancy-related hypercalcemia—5-10% have concurrent primary hyperparathyroidism, and rare cases involve dual pathology 5, 6, 7. The combination of elevated PTH AND PTHrP is exceptionally rare but documented 5.

Phosphate levels provide critical diagnostic clues 1:

• Elevated phosphate → consider hypervitaminosis D, hypophosphatasia, or osteolytic metastases
• Low phosphate → suggests PTHrP-mediated mechanisms (differentiates humoral hypercalcemia from osteolytic disease)